This study tests two drugs, **lurbinectedin** and **durvalumab**, for a type of lung cancer called **extensive stage small cell lung cancer (ES-SCLC)**. This cancer has spread a lot and is usually treated first with a mix of medicines, including **platinum-based chemotherapy**. If the cancer doesn't get worse after the first treatment, the study checks how safe and effective the combination of lurbinectedin and durvalumab is as a continued treatment.

To join, you must have ES-SCLC confirmed by tests, completed 4 cycles of the first treatment, and have a life expectancy of at least 12 weeks. You should not have other serious health conditions like certain lung diseases, other cancers, or be pregnant.

• The study involves using two specific drugs after initial treatment if the cancer hasn’t progressed.
• You need to complete 4 cycles of initial treatment to qualify for this study.
• It's important to discuss potential risks and benefits with your doctor before participating.